– USA, MA – E25Bio, innovators of rapid diagnostics and digital health platforms, today announced the appointment of Prashant Chouta as CEO.
“We are thrilled to welcome Prashant to E25Bio. Prashant comes to the team with a history of success at some of the largest companies in the world. His leadership will undoubtedly help guide E25Bio into its next phase and beyond as it looks to revolutionize pandemic response and prevention through rapid testing and information reporting,” said Ann DeWitt, general partner of The Engine.
Prashant joins the E25Bio team from Uber, where he held executive roles in the Autonomous Vehicle and Micro Mobility divisions. Before Uber, Prashant worked on several key technology platforms at Apple that helped launch several generations of iPhones and the first-generation Apple Watch.
“E25Bio has the opportunity to bring a diagnostic testing platform to the market that can help detect diseases, prevent future pandemics, and save lives,” said Prashant Chouta, incoming CEO. “We look forward to developing our digital platform, accelerating our development pipeline, and bringing our products to the market.”
About E25BIO
Founded in 2018 and based out of The Engine, the company spun out of MIT using technology developed by Dr. Irene Bosch and Dr. Lee Gehrke, the Hermann von Helmholtz Professor of Health Sciences and Technology at MIT. E25Bio develops technology for the rapid diagnosis of dangerous infectious diseases such as dengue, zika, and utilizes a mobile application to track disease data information in real-time. In March 2020, the company developed an antigen test for the novel coronavirus. With investment from Khosla Ventures, E25Bio has since validated the test in clinical studies and looks to commercialize its product for point-of-care testing post-FDA emergency use authorization.
For more information: https://e25bio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.